FOLH1 and Familial prostate cancer: Similarly, the results reported by Baratto and colleagues, comparing RM2-PET and PSMA-PET in patients with biochemically recurrent PCa and by Iagaru and colleagues in patients with newly diagnosed intermediate- or high-risk prostate cancer suggested that the use of both 68Ga-PSMA and 68Ga-DOTA-RM2 provided different and complementary information on PCa [19,32].